Tyrosine Kinase Inhibitors (TKIs) are a class of targeted cancer therapies that block the action of enzymes called tyrosine kinases. These enzymes are responsible for the activation of various proteins by signal transduction cascades, which play a crucial role in the development and progression of cancers. By inhibiting these enzymes, TKIs can effectively disrupt the signaling pathways that promote tumor growth and survival.
